Literature DB >> 19624906

[Expression and significance of Elf-1 and vascular endothelial growth factor in non-small cell lung cancer].

Dong-Xia Yang1, Yan-Chun Han, Lu-Ying Liu, Ning Yu, Xia Wang, Yan Shi.   

Abstract

BACKGROUND AND
OBJECTIVE: The roles of vascular endothelial growth factor (VEGF) in tumor angiogenesis is related with Ets family. Elf-1, a member of Ets family, has seldom been studied. This study aimed to investigate the expression of Elf-1 and VEGF in non-small cell lung cancer (NSCLC), and explore their correlations to clinicopathologic features of NSCLC.
METHODS: Tissue microarray containing 69 specimens of NSCLC and six specimens of normal lung tissues was constructed. The expression of Elf-1 and VEGF was detected by PowerVision-9000 immunohistochemistry.
RESULTS: Elf-1 and VEGF were not detected in all normal tissues; the positive rates of Elf-1 and VEGF were 72.46% and 63.77% in NSCLC, respectively. The expression levels of both Elf-1 and VEGF were significantly related with tumor differentiation, lymphatic metastasis, clinical stage, and postoperative survival time (all P < 0.01). Overexpression of them was related with poor prognosis: the survival rates were significantly lower in positive patients than in negative patients (both P < 0.01). Elf-1 expression was positively correlated to VEGF expression (r = 0.702, P < 0.01).
CONCLUSIONS: The expression of Elf-1 and VEGF in NSCLC is related to differentiation, lymphatic metastasis, clinical stage and prognosis. Detecting their expression in combination can help to predict the malignant behavior of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19624906     DOI: 10.5732/cjc.008.10748

Source DB:  PubMed          Journal:  Ai Zheng


  1 in total

1.  A study of 131iodine-labeling of histamine-indomethacin: its in vivo therapeutic effect and anti-tumor mechanisms in Lewis-bearing lung cancer.

Authors:  Guoxiu Lu; Guoxu Zhang; Caixia Zhang; Chunmei Chen; Ruihao Liu
Journal:  Radiat Oncol       Date:  2013-03-26       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.